Back to top
more

Shire plc (SHPG)

(Delayed Data from NSDQ)

$179.20 USD

179.20
NA

0.00 (0.00%)

Updated Jan 4, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?

On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).

    Ultragenyx Receives Priority Review for rhGUS from FDA

    The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.

      Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug

      Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.

        Company News for May 19, 2017

        Companies in the News are: LB,P,INCY,MRK,SHPG

          Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status

          Sangamo Therapeutics, Inc. (SGMO) announced that the FDA has granted fast track designation to pipeline candidate, SB-525.

            Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde

            Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 22 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents. The company had reported a loss of 32 cents in the year-ago quarter.

              Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat

              Keryx Biopharmaceuticals Inc. (KERX) reported first-quarter 2017 loss of 21 cents per share, narrower than the year-ago loss of 39 cents

                Shire (SHPG) Beats on Q1 Earnings & Sales, Reiterates View

                Shire plc (SHPG) reported first-quarter 2017 earnings of $3.63 per American Depositary Share (ADS), beating the Zacks Consensus Estimate of $3.22 and up 13.8% from the year-ago quarter figure of $3.19.

                  Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat

                  Momenta Pharmaceuticals Inc. (MNTA) reported loss of 46 cents per share in the first quarter of 2017,which was narrower than the Zacks Consensus Estimate loss of $1.09. In fact, the company posted a loss of 35 cents in the year-ago quarter as well.

                    Shire (SHPG) Rare Disease Drug Gets Fast Track Designation

                    Shire plc (SHPG) announced that the FDA has granted Fast Track designation for recombinant ADAMTS13 (SHP655) for the treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP).

                      Is Shire Stock a Good Choice for Value Investors Now?

                      Let's see if Shire plc (SHPG) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

                        Shire's (SHPG) Cinryze Label Expanded for Pediatric Use

                        Shire plc (SHPG) announced that the European Commission (EC) has approved a label extension for drug Cinryze for use in pediatrics.

                          Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat

                          We issued an updated research report on Keryx Biopharmaceuticals, Inc. (KERX) on Mar 15, 2017.

                            Merrimack (MACK) Q4 Loss Lower than Expected, Revenues Top

                            Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 21 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate of a loss of 22 cents.

                              Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View

                              Shire's (SHPG) fourth-quarter results were encouraging with the company beating both top- and bottom-line estimates.

                                Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA

                                Shire plc (SHPG) announced that the FDA has acknowledged receipt of the Class 2 resubmission of a New Drug Application (NDA) for pipeline candidate, SHP465.

                                  Is Shire plc a Great Stock for Value Investors?

                                  Value investing is easily one of the most popular ways to find great stocks in any market environment.

                                    Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug

                                    Shares of Alcobra Ltd. (ADHD) declined 50.7% after the company reported disappointing top-line results from a phase III study, MEASURE, on ADHD drug, metadoxine, extended release.

                                      Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?

                                      Shares of Merrimack Pharmaceuticals Inc (MACK) have increased 47.9% in the last twelve months as the company looks to restructure business.

                                        Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B

                                        Merrimack Pharmaceuticals, Inc. (MACK) announced that it has entered into an agreement with Ipsen for $1.0 billion for Onivyde.

                                          Shire Gets FDA Approval for Label Expansion of Adynovate

                                          Shire announced that the FDA has approved the use of hemophilia A drug, Adynovate,in pediatric patients under 12 years of age

                                            Momenta/Shire's Humira Biosimilar Meets Study Objective

                                            Momenta (MNTA) announced positive data from a phase III study on M923 for the treatment of moderate-to-severe chronic plaque psoriasis.

                                              5 Healthcare Stocks Poised to Trump Q3 Earnings

                                              Medical is one of the many sectors that is witnessing earnings and revenue growth this quarter.

                                                Sheraz Mian headshot

                                                Top Research Reports for Costco, Exxon & Bristol-Myers

                                                Today's Research Daily features new research reports on 16 major stocks, including Costco (COST), ExxonMobil (XOM) and Bristol-Myers (BMY).

                                                  Sheraz Mian headshot

                                                  Top Research Reports for August 4, 2016

                                                  Today's must-read reports are for Shire (SHPG), Colgate-Palmolive Co. (CL) and CME Group Inc. (CME).